Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
NCT05753826Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and fluzoparib in ovarian cancer, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate at 3 years. Started Aug 2023; status: recruiting.
02
Drugs
adebrelimabfluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05753826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753826.